Patients who need new drugs for hepatitis C are divided into: 1, interferon ineffective patients with compensated liver disease. 2, cirrhosis decompensated unable to antiviral therapy . (1) If the liver lesion is far from cirrhosis, only fibrosis, and limited financial strength, you can wait for the first class of regular generic drugs to be marketed and purchased overseas, and take the drugs under the monitoring of medical institutions. During the waiting period, closely monitor liver function and progress, take oral hepatoprotective drugs to slow down the progress of hepatitis C and wait for treatment opportunities. (2) Hepatitis C cirrhosis loss of compensation, urgent treatment after liver transplantation, it is recommended to buy the original drug, limited economic purchase of generic drugs in Bangladesh. A small amount can be purchased to observe the effect (HCVRNA reduction). Because Gilead acquired the patent for this drug for 12 billion and was the first to market, Sovaldi and its upgraded version Harvoni are extremely expensive and widely criticized in the United States. Its competitor, AbbVie’s Viekira/Riba, is already available in Europe and the US (its not recommended for decompensated cirrhosis). Several of the latter companies (Merck, etc.) have drugs entering phase III clinical acceleration in the market. It is believed that the price of originator drugs will also be reduced within six months; the effect of generics can also be verified. In general, the specific analysis of specific conditions, no treatment of patients with long-acting interferon plus hepatoprotective therapy or preferred, at least partly inhibit the virus to protect the liver. If you have the conditions to choose oral medication as soon as possible.